20551068	142	Gottipati P	Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.	Cancer research	2010	57
25708226	142	Tangutoori S	PARP inhibitors: A new era of targeted therapy.	Maturitas	2015	26
25869442	142	Ferguson LR	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.	Seminars in cancer biology	2015	22
20668451	187	Kan Z	Diverse somatic mutation patterns and pathway alterations in human cancers.	Nature	2010	339
19592505	207	Zong Y	ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
10984506	354	Mueller E	Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2000	94
12438256	354	Tepper CG	Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.	Cancer research	2002	83
21436259	354	Lamont KR	Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.	Molecular endocrinology	2011	48
24484606	354	Bancroft EK	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.	European urology	2014	26
26537258	354	Romanel A	Plasma AR and abiraterone-resistant prostate cancer.	Science translational medicine	2015	37
2260966	367	Veldscholte J	A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.	Biochemical and biophysical research communications	1990	150
7795646	367	Visakorpi T	In vivo amplification of the androgen receptor gene and progression of human prostate cancer.	Nature genetics	1995	280
9000575	367	Koivisto P	Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.	Cancer research	1997	132
10363963	367	Taplin ME	Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.	Cancer research	1999	113
12888829	367	Edwards J	Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.	British journal of cancer	2003	78
15389811	367	Miyamoto H	Androgen deprivation therapy for prostate cancer: current status and future prospects.	The Prostate	2004	77
15833816	367	Bohl CE	Structural basis for antagonism and resistance of bicalutamide in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	70
17045208	367	Guo Z	Regulation of androgen receptor activity by tyrosine phosphorylation.	Cancer cell	2006	142
19111796	367	Yuan X	Mechanisms mediating androgen receptor reactivation after castration.	Urologic oncology	2009	82
19345326	367	Xu K	Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.	Cancer cell	2009	69
19366804	367	Steinkamp MP	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.	Cancer research	2009	60
22266865	367	Li Y	AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.	Oncogene	2012	67
22334387	367	Gottlieb B	The androgen receptor gene mutations database: 2012 update.	Human mutation	2012	64
23580326	367	Balbas MD	Overcoming mutation-based resistance to antiandrogens with rational drug design.	eLife	2013	81
23779130	367	Joseph JD	A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.	Cancer discovery	2013	104
23842682	367	Korpal M	An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).	Cancer discovery	2013	103
23859952	367	Shafi AA	Androgen receptors in hormone-dependent and castration-resistant prostate cancer.	Pharmacology and therapeutics	2013	42
24508459	367	An J	Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.	Cell reports	2014	42
25232177	367	Carreira S	Tumor clone dynamics in lethal prostate cancer.	Science translational medicine	2014	68
25274033	367	Geng C	Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.	Cancer research	2014	23
25712683	367	Azad AA	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.	Clinical cancer research 	2015	51
26160840	367	Zhang G	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.	Oncotarget	2015	18
7907678	672	Ford D	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.	Lancet	1994	261
9145676	672	Struewing JP	The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.	The New England journal of medicine	1997	316
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
12237281	672	Thompson D	Cancer Incidence in BRCA1 mutation carriers.	Journal of the National Cancer Institute	2002	206
18349832	672	Antoniou AC	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.	British journal of cancer	2008	99
19060844	672	Clarke B	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.	Modern pathology 	2009	60
19553641	672	Fong PC	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.	The New England journal of medicine	2009	840
22314128	672	Krepischi AC	Germline DNA copy number variation in familial and early-onset breast cancer.	Breast cancer research 	2012	31
22516946	672	Leongamornlert D	Germline BRCA1 mutations increase prostate cancer risk.	British journal of cancer	2012	30
23569316	672	Castro E	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.	Journal of clinical oncology 	2013	59
23810788	672	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	84
24225019	672	Lee JM	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.	Annals of oncology 	2014	55
24478461	672	Laddha SV	Mutational landscape of the essential autophagy gene BECN1 in human cancers.	Molecular cancer research 	2014	37
25224030	672	Mersch J	Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.	Cancer	2015	25
25366685	672	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	144
25454609	672	Castro E	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.	European urology	2015	16
8968085	675	Goggins M	Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.	Cancer research	1996	133
10433620	675	Breast Cancer Linkage Consortium.	Cancer risks in BRCA2 mutation carriers.	Journal of the National Cancer Institute	1999	251
16141007	675	van Asperen CJ	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.	Journal of medical genetics	2005	70
21952622	675	Kote-Jarai Z	BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.	British journal of cancer	2011	43
22133722	1024	Roychowdhury S	Personalized oncology through integrative high-throughput sequencing: a pilot study.	Science translational medicine	2011	165
16854453	1026	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	155
18691549	1027	Majumder PK	A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.	Cancer cell	2008	67
7553621	1029	Herman JG	Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.	Cancer research	1995	241
22179824	1105	Huang S	Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness.	Oncogene	2012	32
22722839	1105	Grasso CS	The mutational landscape of lethal castration-resistant prostate cancer.	Nature	2012	527
25201530	1105	Gao D	Organoid cultures derived from patients with advanced prostate cancer.	Cell	2014	106
25320358	1105	Chen EJ	Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.	Clinical cancer research 	2015	37
11752579	1316	Narla G	KLF6, a candidate tumor suppressor gene mutated in prostate cancer.	Science	2001	120
15735005	1316	Narla G	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.	Cancer research	2005	68
10987273	1499	Truica CI	Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.	Cancer research	2000	102
16023783	1499	Verras M	Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.	Cancer letters	2006	72
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
17126425	1956	McCubrey JA	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.	Biochimica et biophysica acta	2007	423
17404082	1956	Shaffer DR	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	98
19549916	1956	Di Vizio D	Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.	Cancer research	2009	77
14749351	2048	Schaid DJ	The complex genetic epidemiology of prostate cancer.	Human molecular genetics	2004	91
10029066	2064	Bubendorf L	Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.	Cancer research	1999	105
18434311	2064	Najy AJ	The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.	The Journal of biological chemistry	2008	61
17334343	2078	Mehra R	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.	Modern pathology 	2007	85
18483239	2078	Mehra R	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.	Cancer research	2008	78
19190343	2078	Gopalan A	TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.	Cancer research	2009	81
19407851	2078	Han B	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.	Modern pathology 	2009	60
19657377	2078	Clark JP	ETS gene fusions in prostate cancer.	Nature reviews. Urology	2009	84
19933109	2078	Mani RS	Induced chromosomal proximity and gene fusions in prostate cancer.	Science	2009	130
20651988	2078	Park K	Antibody-based detection of ERG rearrangement-positive prostate cancer.	Neoplasia	2010	104
21307934	2078	Berger MF	The genomic complexity of primary human prostate cancer.	Nature	2011	439
25730763	2078	Cooper CS	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.	Nature genetics	2015	51
17671502	2115	Tomlins SA	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.	Nature	2007	275
20927104	2115	Chi P	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.	Nature	2010	80
14532106	2146	Bracken AP	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.	The EMBO journal	2003	331
21367748	2146	Chase A	Aberrations of EZH2 in cancer.	Clinical cancer research 	2011	141
22045636	2261	Foldynova-Trantirkova S	Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.	Human mutation	2012	41
22558290	2346	Kirby BJ	Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.	PloS one	2012	57
15254063	2475	Sansal I	The biology and clinical relevance of the PTEN tumor suppressor pathway.	Journal of clinical oncology 	2004	215
21998291	2475	Wallin JJ	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Molecular cancer therapeutics	2011	64
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
12750453	3169	Gao N	The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes.	Molecular endocrinology	2003	75
22610119	3169	Barbieri CE	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.	Nature genetics	2012	353
23539448	3169	Jin HJ	Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.	Cancer research	2013	39
21072171	3778	Mazar J	The regulation of miRNA-211 expression and its role in melanoma cell invasiveness.	PloS one	2010	46
26085511	3845	Frenel JS	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.	Clinical cancer research 	2015	31
15647368	3853	Petros JA	mtDNA mutations increase tumorigenicity in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	233
27096951	5290	Elwood PC	Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.	PloS one	2016	16
18056989	5292	Xie Y	The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.	The Journal of biological chemistry	2008	57
9072974	5728	Li J	PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.	Science	1997	1013
9090379	5728	Steck PA	Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.	Nature genetics	1997	558
9443392	5728	Suzuki H	Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.	Cancer research	1998	100
9467011	5728	Marsh DJ	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.	Human molecular genetics	1998	118
9560261	5728	Whang YE	Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.	Proceedings of the National Academy of Sciences of the United States of America	1998	137
10564676	5728	Ali IU	Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.	Journal of the National Cancer Institute	1999	113
19402094	5728	Sircar K	PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.	The Journal of pathology	2009	70
20533527	5728	McBride KL	Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly.	Autism research 	2010	61
21878536	5728	Lotan TL	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.	Clinical cancer research 	2011	73
24135135	5728	Haffner MC	Tracking the clonal origin of lethal prostate cancer.	The Journal of clinical investigation	2013	95
26546618	5728	Aparicio AM	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.	Clinical cancer research 	2016	11
11799394	6041	Carpten J	Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.	Nature genetics	2002	118
12415269	6041	Casey G	RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.	Nature genetics	2002	92
18823818	6041	Fischer N	Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer.	Journal of clinical virology 	2008	80
9771714	6790	Zhou H	Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.	Nature genetics	1998	306
12649205	7157	Pihan GA	Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.	Cancer research	2003	102
19349354	7157	Seligson DB	Global levels of histone modifications predict prognosis in different cancers.	The American journal of pathology	2009	109
22965953	7157	Lehmann S	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	Journal of clinical oncology 	2012	58
25827447	7157	Hong MK	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.	Nature communications	2015	39
24563616	8405	Blattner M	SPOP mutations in prostate cancer across demographically diverse patient cohorts.	Neoplasia	2014	27
22841674	10481	Karlsson R	A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.	European urology	2014	33
23064873	10481	Xu J	HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).	Human genetics	2013	40
23104005	10481	Gudmundsson J	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer.	Nature genetics	2012	72
26510020	11200	Mateo J	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.	The New England journal of medicine	2015	128
27433846	11200	Pritchard CC	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.	The New England journal of medicine	2016	29
10786676	51741	Bednarek AK	WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.	Cancer research	2000	104
